580 related articles for article (PubMed ID: 8587197)
21. The HER2/neu-derived peptide p654-662 is a tumor-associated antigen in human pancreatic cancer recognized by cytotoxic T lymphocytes.
Peiper M; Goedegebuure PS; Linehan DC; Ganguly E; Douville CC; Eberlein TJ
Eur J Immunol; 1997 May; 27(5):1115-23. PubMed ID: 9174600
[TBL] [Abstract][Full Text] [Related]
22. Regulatory T-cell response and tumor vaccine-induced cytotoxic T lymphocytes in human melanoma.
Chakraborty NG; Chattopadhyay S; Mehrotra S; Chhabra A; Mukherji B
Hum Immunol; 2004 Aug; 65(8):794-802. PubMed ID: 15336780
[TBL] [Abstract][Full Text] [Related]
23. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
[TBL] [Abstract][Full Text] [Related]
24. Recognition of shared melanoma antigen by HLA-A2-restricted cytolytic T cell clones derived from human tumor-infiltrating lymphocytes.
Viret C; Davodeau F; Guilloux Y; Bignon JD; Semana G; Breathnach R; Jotereau F
Eur J Immunol; 1993 Jan; 23(1):141-6. PubMed ID: 8419164
[TBL] [Abstract][Full Text] [Related]
25. Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.
Yamazaki K; Spruill G; Rhoderick J; Spielman J; Savaraj N; Podack ER
Cancer Res; 1999 Sep; 59(18):4642-50. PubMed ID: 10493519
[TBL] [Abstract][Full Text] [Related]
26. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected.
Ramarathinam L; Sarma S; Maric M; Zhao M; Yang G; Chen L; Liu Y
J Immunol; 1995 Dec; 155(11):5323-9. PubMed ID: 7594546
[TBL] [Abstract][Full Text] [Related]
27. The expression of mouse gene P1A in testis does not prevent safe induction of cytolytic T cells against a P1A-encoded tumor antigen.
Uyttenhove C; Godfraind C; Lethé B; Amar-Costesec A; Renauld JC; Gajewski TF; Duffour MT; Warnier G; Boon T; Van den Eynde BJ
Int J Cancer; 1997 Jan; 70(3):349-56. PubMed ID: 9033639
[TBL] [Abstract][Full Text] [Related]
28. The shared tumor-specific antigen encoded by mouse gene P1A is a target not only for cytolytic T lymphocytes but also for tumor rejection.
Brändle D; Bilsborough J; Rülicke T; Uyttenhove C; Boon T; Van den Eynde BJ
Eur J Immunol; 1998 Dec; 28(12):4010-9. PubMed ID: 9862337
[TBL] [Abstract][Full Text] [Related]
29. Identification of a unique antigen peptide pRL1 on BALB/c RL male 1 leukemia recognized by cytotoxic T lymphocytes and its relation to the Akt oncogene.
Uenaka A; Ono T; Akisawa T; Wada H; Yasuda T; Nakayama E
J Exp Med; 1994 Nov; 180(5):1599-607. PubMed ID: 7964448
[TBL] [Abstract][Full Text] [Related]
30. Distinct patterns of cytolytic T-cell activation by different tumour cells revealed by Ca
Frick M; Mouchacca P; Verdeil G; Hamon Y; Billaudeau C; Buferne M; Fallet M; Auphan-Anezin N; Schmitt-Verhulst AM; Boyer C
Immunology; 2017 Feb; 150(2):199-212. PubMed ID: 27716898
[TBL] [Abstract][Full Text] [Related]
31. CTL response and protection against P815 tumor challenge in mice immunized with DNA expressing the tumor-specific antigen P815A.
Rosato A; Zambon A; Milan G; Ciminale V; D'Agostino DM; Macino B; Zanovello P; Collavo D
Hum Gene Ther; 1997 Aug; 8(12):1451-8. PubMed ID: 9287145
[TBL] [Abstract][Full Text] [Related]
32. Cytotoxic T lymphocytes to an unmutated tumor rejection antigen P1A: normal development but restrained effector function in vivo.
Sarma S; Guo Y; Guilloux Y; Lee C; Bai XF; Liu Y
J Exp Med; 1999 Mar; 189(5):811-20. PubMed ID: 10049945
[TBL] [Abstract][Full Text] [Related]
33. Murine leukemia RL male 1 and sarcoma Meth A antigens recognized by cytotoxic T lymphocytes (CTL).
Uenaka A; Nakayama E
Cancer Sci; 2003 Nov; 94(11):931-6. PubMed ID: 14611667
[TBL] [Abstract][Full Text] [Related]
34. The long-standing quest for tumor rejection antigens.
van der Bruggen P
Clin Immunol Immunopathol; 1994 Jun; 71(3):248-52. PubMed ID: 8200126
[TBL] [Abstract][Full Text] [Related]
35. Tumor antigens recognized by T lymphocytes.
Van den Eynde BJ; Boon T
Int J Clin Lab Res; 1997; 27(2):81-6. PubMed ID: 9266277
[TBL] [Abstract][Full Text] [Related]
36. Photodynamic therapy of murine mastocytoma induces specific immune responses against the cancer/testis antigen P1A.
Mroz P; Vatansever F; Muchowicz A; Hamblin MR
Cancer Res; 2013 Nov; 73(21):6462-70. PubMed ID: 24072749
[TBL] [Abstract][Full Text] [Related]
37. Targeted tumor coating with antigenic, CTL-recognizable peptides via Annexin A5 chimeric constructs following chemotherapy redirects adaptive CD8+ T cell immunity for tumor clearance.
Kang TH; Yang A; Tsai Y; Ferrall L; Hung CF
Cell Mol Immunol; 2021 Jun; 18(6):1578-1580. PubMed ID: 33139904
[No Abstract] [Full Text] [Related]
38. Database of T cell-defined human tumor antigens: the 2013 update.
Vigneron N; Stroobant V; Van den Eynde BJ; van der Bruggen P
Cancer Immun; 2013; 13():15. PubMed ID: 23882160
[TBL] [Abstract][Full Text] [Related]
39. Tumor antigens recognized by T cells.
Boon T; Coulie PG; Van den Eynde B
Immunol Today; 1997 Jun; 18(6):267-8. PubMed ID: 9190110
[No Abstract] [Full Text] [Related]
40. Retraction: Molecular Mechanism of MART-1
Cancer Res; 2017 Jul; 77(13):3718. PubMed ID: 28674203
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
